

## STRATEGIC COLLABORATION BETWEEN BIONEER A/S & NATIONAL BIOLOGICS FACILITY

---

**Bioneer A/S announces a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins.**

*Copenhagen, September 16<sup>th</sup>, 2021.* Bioneer A/S, a globally operating Danish specialty-CRO creating and commercializing innovative research service solutions for early stage drug development and *in vitro* modelling, announced today that it has entered a strategic collaboration with the National Biologics Facility (NBF). The entity, previously named CHO CORE, is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk Foundation, NBF was established in 2012 at the Technical University of Denmark (DTU). This collaboration will enable Bioneer to offer end-to-end non-GMP production of recombinant proteins utilizing both microbial and mammalian expression platforms.

Bioneer and NBF complement each other's capabilities. NBF brings broad experience in CHO cell line engineering and expert understanding of stable protein expression in CHO cells. Bioneer brings nearly 40 years of commercial and scientific experience creating customized service solutions in the field of expression and production of special proteins and antibodies.

Jette Asboe Lassen, CBO at Bioneer, says: "We are excited to join forces with NBF and to be able to expand our offering and capacity to clients seeking mammalian cell line development and production capabilities for recombinant proteins."

Bjørn Voldborg, Director at NBF, says: "I am extremely excited about this collaboration that will allow us to deploy the expertise, know-how, and infrastructure for protein and cell line development in mammalian cells we have generated over the past 8 years at DTU."

With this partnership, the recombinant protein production capacity available to Bioneer will be nearly doubled. State-of-the-art, Copenhagen-based, laboratories for mammalian cell line development and protein expression are established at NBF and similar facilities will be ready at the end of the year at Bioneer, which is currently expanding its laboratories, including the construction of brand-new protein laboratories.

The collaboration between Bioneer and NBF will be of great benefit to the national and international biotech and pharma industries, in a climate where the global need for facilities dedicated to the development of biologically based therapeutics and specialty proteins is more important than ever.

For immediate release

### About Bioneer A/S

*Bioneer A/S is a trusted strategic R&D partner to biotech and pharmaceutical companies operating globally. We are a specialty-CRO, creating customized and innovative research service solutions through our unique know-how and advanced technologies. As an extended R&D team for our clients, we help develop and produce early drug candidates and generate key pre-clinical insights into their mechanisms, efficacy, and safety. With dedicated and highly skilled employees, state-of-the-art laboratory facilities, and a history of nearly 40 years of operation, we deliver innovative solutions to the Life Science industry, as a Danish government-approved Research and Technology Organization. [www.bioneer.dk](http://www.bioneer.dk)*

### About the National Biologics Facility

*The National Biologics Facility (NBF) is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk Foundation, it was established in 2012 at the Technical University of Denmark (DTU) and is today part of DTU Bioengineering. We offer industrial and academically based expertise and uniquely customized services for the early discovery and developmental stages of protein-based therapeutics, from early drug discovery to pre-clinical development, using standard as well as more advanced in-house developed mammalian production systems. Our combined industrial and academic background enables us to provide innovative solutions for clients to reach their goals and improve and accelerate their projects towards clinical phases, manufacturing, and market. <https://nbf.dtu.dk/>*



### Press contact:

Sophie Rauff-Manco  
Marketing Manager  
Bioneer A/S

+45 45 16 04 44

+45 21 67 97 34

[srm@bioneer.dk](mailto:srm@bioneer.dk)